Search alternatives:
significant portion » significant proportion (Expand Search), significant positive (Expand Search), significant correlation (Expand Search)
increase decrease » increased release (Expand Search), increased crash (Expand Search)
portion decrease » proportional decrease (Expand Search), point decrease (Expand Search)
significant portion » significant proportion (Expand Search), significant positive (Expand Search), significant correlation (Expand Search)
increase decrease » increased release (Expand Search), increased crash (Expand Search)
portion decrease » proportional decrease (Expand Search), point decrease (Expand Search)
-
1301
-
1302
-
1303
-
1304
-
1305
-
1306
-
1307
-
1308
-
1309
-
1310
Trends analysis in diabetes mellitus diagnosis according to relative handgrip strength.
Published 2024Subjects: -
1311
-
1312
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
1313
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
1314
Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
1315
-
1316
-
1317
-
1318
-
1319
-
1320